Tag - Ami Fadia


SVB Leerink starts Amryt Pharma at OP; PT $40

SVB Leerink launched coverage of Amryt Pharma (NASDAQ:AMYT) with an “outperform” rating and $40 price target. The stock closed at $14.15 on Feb. 12. “Filsuvez is poised to be the first approved treatment for...

SVB Leerink cuts Amneal Pharma to MP; PT to $3 from $4

SVB Leerink downgraded Amneal Pharmaceuticals (NYSE:AMRX) to “market perform” from “outperform” and lowered its price target to $3 from $4 after the company cut its guidance. The stock closed at $2.76 on Nov. 6. Analyst...

SVB Leerink ups AMAG Pharma PT to $14 from $9

SVB Leerink raised its price target for AMAG Pharmaceuticals (NASDAQ:AMAG) to $14 from $9 ahead of an FDA advisory committee meeting on Oct. 29. The stock closed at $11.50 on Oct. 4. “Based on our MEDACorp survey of 50...


SVB Leerink cuts Mallinckrodt PT to $2 from $7

SVB Leerink reduced its price target for “market perform” rated Mallinckrodt (NYSE:MNK) to $2 from $7, reflecting a higher risk profile for the company. The stock closed at $1.59 on Sept. 5. “While we believe that the...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.